Diabetic Perspectives

Rev Diabet Stud, 2005, 2(3):165-176 DOI 10.1900/RDS.2005.2.165

Approaches Towards Endogenous Pancreatic Regeneration

Meenal Banerjee, Meghana Kanitkar, Ramesh R. Bhonde

Tissue Engineering and Banking Laboratory, National Centre for Cell Science, Ganeshkhind, Pune-411007, India.
Address correspondence to: Ramesh R. Bhonde, e-mail: rrbhonde@nccs.res.in.

Keywords: diabetes, pancreatic regeneration, biomolecules, adult stem cells, replication


The phenomenon of pancreatic regeneration in mammals has been well documented. It has been shown that pancreatic tissue is able to regenerate in several species of mammal after surgical insult. This tissue is also known to have the potential to maintain or increase its β-cell mass in response to metabolic demands during pregnancy and obesity. Since deficiency in β-cell mass is the hallmark of most forms of diabetes, it is worthwhile understanding pancreatic regeneration in the context of this disease. With this view in mind, this article aims to discuss the potential use in clinical strategies of knowledge that we obtained from studies carried out in animal models of diabetes. Approaches to achieve this goal involve the use of biomolecules, adult stem cells and gene therapy. Various molecules, such as glucagon-like peptide-1, β-cellulin, nicotinamide, gastrin, epidermal growth factor-1 and thyroid hormone, play major roles in the initiation of endogenous islet regeneration in diabetes. The most accepted hypothesis is that these molecules stimulate islet precursor cells to undergo neogenesis or to induce replication of existing β-cells, emphasizing the importance of pancreas-resident stem/progenitor cells in islet regeneration. Moreover, the potential of adult stem cell population from bone marrow, umbilical cord blood, liver, spleen, or amniotic membrane, is also discussed with regard to their potential to induce pancreatic regeneration.

Fulltext: HTML , PDF (364KB)

This article has been cited by other articles:

A review on endogenous regenerative technology in periodontal regenerative medicine

Chen FM, Zhang J, Zhang M, An Y, Chen F, Wu ZF

Biomaterials 2010. 31(31):7892-7927

Human umbilical cord blood as an emerging stem cell therapy for diabetes mellitus

Reddi AS, Kuppasani K, Ende N

Curr Stem Cell Res Ther 2010. 5(4):356-361

Antihyperglycemic activity of catharanthus roseus leaf powder in streptozotocin-induced diabetic rats

Rasineni K, Bellamkonda R, Singareddy SR, Desireddy S

Pharmacogn Res 2010. 2(3):195-201

Islet neogenesis-associated protein pentadecapeptide (INGAP-PP): mechanisms involved in its effect upon beta-cell mass and function

Madrid V, Del Zotto H, Maiztegui B, Raschia MA, Alzugaray ME, Boschero AC, Barbosa HC, Flores LE, Borelli MI, Gagliardino JJ

Regul Pept 2009. 157(1-3):25-31

Can splenocytes enhance pancreatic beta-cell function and mass in 90% pancreatectomized rats fed a high fat diet?

Park S, Hong SM, Ahn IS

Life Sci 2009. 84(11-12):358-363

The influence of pancreas-derived stem cells on scaffold based skin regeneration

Salem H, Ciba P, Rapoport DH, Egana JT, Reithmayer K, Kadry M, Machens HG, Kruse C

Biomaterials 2009. 30(5):789-796

Surgical conditions of the Canine and Feline pancreas

Havlicek M, Franklin A

Aust Vet Pract 2008. 38(4):146-152

Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer

Mimeault M, Batra SK

Gut 2008. 57(10):1456-1468

Nicotinamide: A cytoprotectant against streptozotocininduced diabetic damage in wistar rat brains

Ibrahim SS, Rizk SM

Afr J Biochem Res 2008. 2(8):174-180

Stem cell potential for type 1 diabetes therapy

Roche E, Ramirez M, Ramirez-Castillejo C, Gomez-Mauricio G, Uson J

Cent Europ J Biol 2007. 2(4):449-480

Advancements of stem-cell therapy for type 1 diabetes mellitus

Li H, We J, Mu C

Chin Bull Life Sci 2007. 19(4):401-408